PD-L1 Measured by Blood Test Reveals Important Clinical Information

MONMOUTH JUNCTION, N.J., March 12, 2025 /PRNewswire/ -- Researchers from Creatv Bio, Division of Creatv MicroTech, Inc. (Monmouth Junction, NJ) and The Mayo Clinic (Jacksonville, FL), in collaboration with BriaCell Therapeutics Corporation (Philadelphia, PA), have shown in a study of Metastatic Breast Cancer (mBC) patients treated with SV-BR-1-GM vaccine in combination with an immunotherapy drug, that the vaccine can change the PD-L1 expression of the tumor. The PD-L1 expression is determined by the LifeTracDx^® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD-L1 marker.

The data was presented at the annual San Antonio Breast Cancer Symposium (SABCS) in December 2024, and is titled: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes in a Phase 1/2 Clinical Trial Using SV-BR-1-GM Vaccine with the Check Point Inhibitor Retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis. https://creatvbio.com/posters.

The data of 36 patients showed that a decrease in CTCs/CAMLs numbers significantly correlated with better Progression Free Survival and trended for better Overall Survival. In addition, SV-BR-1_GM therapy appeared to upregulate PD-L1 expression in 15 patients which correlated with better responses to combination treatment with the anti-PD-L1 check point inhibitor.

LifeTracDx^® can predict treatment response, and at the same time provide information about companion diagnostics for a wide variety of tumor markers. The test isolates CAMLs and CTCs from the blood of the cancer patient. CAMLs are macrophages that have engulfed tumor cells from tumor site. Thus, both CAMLs and CTCs contain tumor material, ideal for companion diagnostic.

About Creatv Bio

Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and to pharma companies to support drug development from its CLIA/CAP laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx^® blood tests have many other applications: predicting response to a new therapy within just 30 days, providing PD-L1 companion diagnostics, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening. For a complete listing of our journal publications and posters, please visit our website at https://creatvbio.com/.

For more information contact:

View original content to download multimedia:https://www.prnewswire.com/news-releases/pd-l1-measured-by-blood-test-reveals-important-clinical-information-302399042.html

SOURCE Creatv MicroTech, Inc.